ArticleBioMed research international2014
Amelioration of colitis in mouse model by exploring antioxidative potentials of an indigenous probiotic strain of Lactobacillus fermentum Lf1.
Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- Cytoprotective Effects of Lactic Acid Bacteria and Yeast Cell-Free Supernatants Against Acrylamide-Induced Damage in Caco-2 Cells.Probiotics and antimicrobial proteins · 2026Article
- In Vivo Evaluation of the Effect ofInternational journal of molecular sciences · 2026Article
- Nrf2 as a Molecular Guardian of Redox Balance and Barrier Integrity in IBD.Antioxidants (Basel, Switzerland) · 2025Review
- Antioxidant Activity of Bovine Colostrum in the Colon of a Mouse Model of TNBS-Induced Colitis.Antioxidants (Basel, Switzerland) · 2025Article
- Exploring the antimicrobial potential of lactobacilli against early-stage and mature biofilms ofFrontiers in chemistry · 2025Article
- Protective Potential ofJournal of microbiology and biotechnology · 2024Article
- The ameliorating effect of limosilactobacillus fermentum and its supernatant postbiotic on cisplatin-induced chronic kidney disease in an animal model.BMC complementary medicine and therapies · 2023Article
- Limosilactobacillus fermentum, Current Evidence on the Antioxidant Properties and Opportunities to be Exploited as a Probiotic Microorganism.Probiotics and antimicrobial proteins · 2022Review
- Article
- Protective effect ofFrontiers in microbiology · 2022Article
- Protective Effect of Lacticaseibacillus casei CRL 431 Postbiotics on Mitochondrial Function and Oxidative Status in Rats with Aflatoxin BProbiotics and antimicrobial proteins · 2021Article
- Article
- Article
- Ameliorative Effect of Surface Proteins of Probiotic Lactobacilli in Colitis Mouse Models.Frontiers in microbiology · 2021Article
- Protective Effect of the Intracellular Content from Potential Probiotic Bacteria against Oxidative Damage Induced by Acrylamide in Human Erythrocytes.Probiotics and antimicrobial proteins · 2020Article
- Application ofAnimals : an open access journal from MDPI · 2020Review
- Probiotic Clostridium butyricum Improves the Growth Performance, Immune Function, and Gut Microbiota of Weaning Rex Rabbits.Probiotics and antimicrobial proteins · 2019Article
- Assessing the Safety and Efficacy of Lactobacillus plantarum MTCC 5690 and Lactobacillus fermentum MTCC 5689 in Colitis Mouse Model.Probiotics and antimicrobial proteins · 2019Article
- Modulatory Effect of the Intracellular Content of Lactobacillus casei CRL 431 Against the Aflatoxin BProbiotics and antimicrobial proteins · 2019Article
- Methods to Assess the Antioxidative Properties of Probiotics.Probiotics and antimicrobial proteins · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on the preliminary screening of eight indigenous putative probiotic Lactobacilli, Lactobacillus fermentum Lf1 was selected for assessing its antioxidative efficacy in DSS colitis mouse model based on its ability to enhance the expression of "Nrf2" by 6.43-fold and malondialdehyde (MDA) inhibition by 78.1 ± 0.24% in HT-29 cells under H2O2 stress. The Disease Activity Index and histological scores of Lf1-treated mice were lower than the control group. However, expression of "Nrf2" was not observed in Lf1-treated mice. A significant increase in the expression of antioxidative enzymes such as SOD2 and TrxR-1 was recorded in both of the groups. The expression of SOD2 was significantly downregulated in colitis-induced mice by -100.00-fold relative to control group, and the downregulation was considerably reduced to -37.04-fold in colitis Lf1 treatment group. Almost, a similar trend was recorded in case of "thioredoxin" expression, though "CAT" was refractile to expression. The Lf1-treated group had decreased malondialdehyde level as compared to colitis control (37.92 ± 6.31 versus 91.13 ± 5.76 μM/g). These results point towards Lf1-induced activation of the antioxidant enzyme system in the mouse model and its prospects to be explored as a new strategy for IBD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.